Targeting of liposomes to solid tumors: The case of sterically stabilized anti-HER2 immunoliposomes

Journal of Liposome Research

Volumn 7, Issue 4, 1997, Pages 391-417

  Kirpotin, Dmitri B ^a,b,c   Park, John W ^a,b,c   Hong, Keelung ^a,b,c   Shao, Yi ^a,b,c   Shalaby, Refaat ^a,b,c   Colbern, Gail ^a,b,c   Benz, Christopher C ^a,b,c   Papahadjopoulos, Demetrios ^a,b,c  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DOXORUBICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; ONCOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GRAFT; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0031473207     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.3109/08982109709035509     Document Type: Review

References (74)

1. Papahadjopoulos, D. 1995. 30-Year progress for liposomes: from serendipity to molecular design. J. Liposome Res. 5:ix-xiv.
2. Lasic, D.D. and Papahadjopoulos, D. 1995. Liposomes revisited. Science 267:1275-1276.
3. Leserman, L. and Machy, P. 1987. Ligand targeting of liposomes. In "Liposomes. From Biophysics to Therapeutics". M.J. Ostro (Ed.). Marcell Dekker, New York, p. 157-194.
4. Ranade, V.V. 1989. Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers. J. Clin. Pharmacol. 29:685-694.
5. Straubinger, R.M., Lopez, N.G., Debs, R.J, Hong, K. and Papahadjopoulos, D. 1988. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. 48:5237-5245.
6. Allen, T.M. and Chonn, A. 1987. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223:42-46.
7. Gabizon, A. and Papahadjopoulos, D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85: 6949-6953.
8. Blume, G., and Cevc, G. 1990. Liposomes for the sustained drug release hi vivo. Biochim. Biophys. Acta 1029:91-97.
9. Klibanov, A.L., Maruyama, K., Torchilin, V.P. and Huang, L. 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:235-237.
10. Papahadjopoulos, D., Alien, T., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.-D., Woodle, M.C., Lasic, D.D., Redemann, C. and Martin, FJ. 1991. Sterically stabilized liposomes: Improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88:11460-11464.
11. Torchilin, V.P., Klibanov, A.L., Huang, L., O'Donnell, S., Nossiff, N.D. and Khaw, B.A. 1992. Targeted accumulation of polyethylene glycolcoated immunoliposomes in infarcted rabbit myocardium. FASEB J. 6:2716-2719.
12. Klibanov, A.L., Maruyama, K., Beckerleg, A.M., Torchilin, V.P. and Huang, L. 1991. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation lifetime of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1062:142-148.
13. Torchilin, V.P., Papisov, M.I., Bogdanov, A.A., Trubetskoy, V.S. and Omelyanenko, V.G. 1995. Molecular mechanism of liposome and immunoliposome steric protection with poly(ethylene glycol). In "Stealth Liposomes". D. Lasic, F. Martin (Eds.). CRC Press, Boca Raton, FL, p.5162.
14. Allen, T.M., Brandeis, E., Hansen, C.B., Kao, G.Y. and Zalipsky, S. 1995. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237:99-108.
15. Hansen, C.B., Kao, G.Y., Moase, E.H., Zalipsky, S. and Allen, T.M. 1995. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239:133-144.
16. Zalipsky, S., Hansen, C.B., Lopes de Menezes, D., E and Allen, T.M. 1996. Long-circulating, polyethylene glycol-grafted immunoliposomes. J. Controlled Release 39:153-161.
17. Kirpotin, D., Park, J.W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C.C. and Papahadjopoulos, D. 1997. Sterically stabilized anti-HER2 immunoliposomes: desin and targeting to human breast cancer cells in vitro. Biochemistry 36:66-75.
18. Park, J.W., Hong, K., Carter, P., Asgari, H., Guo, L.Y., Wirth, C., Shalaby, R., Kotts, C., Keller, G.A., Wood, W.I., Papahadjopoulos, D and Benz, C.C. 1995. Development of anti-pi 85HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 92:1327-1331.
19. Park, J.W., Hong, K., Kirpotin, D.B., Papahadjopoulos, D. and Benz C.C. 1997. Immunoliposomes for cancer treatment. Adv. Pharmacol. 40:399-436.
20. Park, J.W., Hong, K., Kirpotin, D.B., Meyer, O., Papahadjopoulos, D. and Benz C.C. 1997. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 118:153-160.
21. Park, J.W., Colbern, G., Hong, K., Kirpotin, D., Shao, Y., Baselga, J., Moore, D., Papahadjopoulos, D. and Benz, C.C. 1997. Targeted intracellular drug delivery via anti-HER2 immunoliposomes yields superior antirumor efficacy. Proc. ASCO, 16:430a.
22. Meyer, O., Kirpotin, D., Hong, K., Sternberg, B., Park, J.W., Woodle, M.C. and Papahadjopoulos, D. 1997. Poly(ethylene glycol)-coated cationic liposomes as carriers for cellular delivery of antisense oligonucleotides. J. Biol. Chem. (submitted)
23. Hynes, N.E. and Stern, D.F. 1994. The biology of erbB-2/neu/HER2 and its role in cancer. Biochim. Biophys. Acta 1198:165-184.
24. Carraway, K.L. and Cantley, L.C. 1994. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5-8.
25. Slamon, D.J., Clark, G.Mm, Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. 1987. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235:177-182.
26. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A. and Press, M. 1989. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
27. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J.T., Dodge, R., Clarke-Pearson, D.L., Marks, P., McKenzie, S., Yin, S. and Bast, R.C. 1990. Overexpression of HER2/neu is associated with poor susvival in advanced epithelial ovarian cancer. Cancer Res. 50:4087-4091.
28. Berchuck, A., Rodriguez, G., Kinney, R.B., Soper, J.T., Dodge, R.K., Clarke-Pearson, D.L. and Bast, R.C. 1991. Overexpression of HER2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstetrics Gynecol. 164:15-21
29. Kem, J.A., Schwartz, D.A., Nordberg, J.E., Weiner, D.B., Greene, M.I., Torney, L. and Robinson, R.A. 1990. p185neu expression in human lung adenocarcinomas predict shortened survival. Cancer Res. 50:5184-5191.
30. Yokota, J., Yamamoto, T., Miyajima, N., Toyoshima, K., Nomura, N., Sakamoto, H., Yoshida, T., Terada, M. and Sugimura, T. 1988. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of v-erbA homologue. Oncogene 2:283-287.
31. Park, J.B., Rhim, J.S., Park, S.C., Kimm, S.W. and Kraus, M.H. 1989. Amplification, Overexpression and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res. 49:6605-6609.
32. Lei, A., Appert, H.E., Nakata, B., Domenico, D.R., Kim, K. and Howard, J.M. 1995. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int. J. Pancreatology 17:15-21.
33. Zhau, H.E, Zhang, X., von Eschenbach, A.C., Scorsone, K., Babaian, R.J., Ro, J.Y. and Hung, M.C. 1990. Amplification and expression of the c-erbB-2/neu proto-oncogene in human bladder cancer. Molec. Carcinogenesis 3:254-257.
34. Gu, K., Mes-Masson, A.-M., Gauthier, J. and Saad, F. 1996. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett. 99:185-189.
35. VandeVijver, M.J., Peterse , M.L., Mooi, W.J., Wisman, O., Lomans, J., Dalesio, O. and Nusse, R. 1988. Neu-protein expression in breast cancer. New Engl. J. Med. 319:1239-1245.
36. Liu, E., Thor, A., He, M., Barcos, M., Ljung, B.M. and Benz, C.C. 1992. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7:1027-1032.
37. Lewis, G.D., Figari, I., Fendly, B.M., Wong, W.-L., Carter, P., Gorman, C. and Shepard, H.M. 1993. Differential responses of human tumor cell lines to anti-pi85HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37:255-263.
38. Press, M.F., Cordon-Cardo, C. and Slamon, D.J. 1990. Expression of the HER-2/neu proto-oncogene in normal humad adult and fetal tissues. Oncogene 5: 953-962.
39. Niehans, G.A., Singleton, T. P., Dykoski, D. and Kiang, D.T. 1993. Stability of HER-2/neu expression over time and at multiple metastatic sites. J. Natl. Cancer Inst. 85:1230-1235.
40. Tagliabue, E., Centis, P., Campiglio, M., Mastroiannini, A., Martignone, S, Pellegrini, R., Casalani, P., Lanzi, C., Menard, S. and Colnaghi, M.I. 1991. Selecion of monoclonal antibodies which induce internalization and phosphorylation of p!85HER2 and growth inhibition of cells with HER2/neu gene amlpifkation. Int. J. Cancer 47: 933-937.
41. Sarup, J.C., Johnson, R.M., King, K.L., Fendly, B.M., Lipari, M.T., Napier, M.A., Ullrich, A. and Shepard, H.M. 1991. Characterization of an anti-pi 85HER2 monoclonal antibody that stimulated receptor function and inhibits tumor cell growth. Growth Regulation 37: 72-82.
42. Hurwitz, E., Stancovski, I., Sela, M. and, Yarden, Y. 1995. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA 92:3553-3557.
43. Fendly, B.M., Winget, M., Hudziak, R.M., Lipari, M.T., Napier, M.A. and Ullrich, A. 1990. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550-1558.
44. Schier, R., Marks, J.D., Wolf, E.J., Apell, G., Wong, C., McCartney, J.E., Bookman, M.A., Huston, J.A., Houston, L.L., Weiner, L.M., Adams, G.P. 1995. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1:73-81.
45. Schier, R., McCal, A., Adams, O.P., Marshall, K.W., Merritt, H., Yim, M., Craford, R.S., Weiner, L.M., Marks, C., Marks, J.D. 1996. Isolation of picomolar affinity anti-c-erbB-2 single chain Fv by molecular evolution of the complementary determining regions in the center of the antibody binding site. J. Mol. Biol. 263:551-567.
46. Park, J.W., Stagg, R., Lewis, G.D., Carter, P., Maneval, D., Slamon, D.J., Jaffe, H. and Shepard, H.M., 1992. Anti-pi85HER2 monoclonal antibodies: biological properties and potential for immunotherapy. In "Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer". R.B. Dickson and M.E. Lippman (Eds). Kluwer, Boston, MA, p. 193-211.
47. Carter, P., Presta, L., Gorman, C.M., Ridgway, J.B.B., Henner, D., Wong, W.L.T., Rowland, A.M., Kotts, C., Carver, M.E. and Shepard, H.M. 1992. Humanization of an anti-pi85HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89:4285-4289.
48. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, C.A., Moore, J., Rosen, P.P., Twaddell, T., Henderson, I.C. and Norton, L. 1996. Phase II study of weekly intravenous recombinant humanized anti-p!85HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin. Oncol. 14:737-744.
49. Papahadjopoulos, D., Jacobson, K., Nir, S. and Isac, T. 1973. Phase transitions in phospholipid vesicles, fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim. Biophys. Acta 311:330-348.
50. Oison, F., Hunt, C.A., Szoka, F.C., Vail, W.J. and Papahadjopoulos, D. 1979. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim. Biophys. Acta 557: 9-23.
51. Martin, F. and Papahadjopoulos, D. 1982. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J. Biol. Chem. 257:286-288.
52. Shahinian, S. and Silvius, J.R. 1995. A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes. Biochim. Biophys. Acta 1239: 157-167.
53. Loughrey, H.C., Choi, L.S., Cullis, P.R. and Bally, M.B. 1990. Optimized procedures for the coupling of proteins to liposomes. J. Immunol. Methods 132:25-35.
54. Bredehorst, R., Ligler, F.S., Kusterbeck, A.W., Chang, EX., Gaber, B.P. and Vogel, C.-W. 1986. Effect of covalent attachment of immunoglobulin fragments on liposomal integrity. Biochemistry 25:5693-5698.
55. Hristova, K. and Needham, D. 1995. Physical properties of polymergrafted bilayers. In "Stealth Liposomes". D. Lasic, F. Martin (Eds). CRC Press, Boca Raton, FL, p. 35-49.
56. Mori, A., Klibanov, A.L., Torchilin, V.P. and Huang, L. 1991. Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 284:263-266.
57. Huang, S.K., Mayhew, E., Gilani, S., Lasic, D.D., Martin, F.J. and Papahadjopoulos, D. 1992. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52:6774-6781.
58. Working, P.W., Newman, M., Huang, S.K., Vaage, J., Mayhew, E. and Lasic, D.D. 1994. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes. J. Liposome Res. 4:667-687.
59. Bogner, J.R. and Goebel, F.-D. 1995. Efficacy of Dox-SL (Stealth® liposomal doxorubicin) in the treatment of advanced AIDS-related Kaposi's sarcoma. In "Stealth Liposomes". D. Lasic, F. Martin (Eds). CRC Press, Boca Raton, FL, p.267-278.
60. Haran, G., Cohen, R., Bar, L.K. and Barenholz, Y. 1993. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1149:180-184.
61. Daleke, D.L., Hong, K. and Papahadjopoulos, D. 1990. Endocytosis of liposomes by macrophages: binding, acidification, and leakage of liposomes monitored by a new fluorescence assay. Biochim. Biophys. Acta 1024:352-366.
62. Maruyama, K., Takizawa, T., Yuda, T., Kennel, S.J., Huang, L. and Iwatsuru, M. 1995. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their 'distal terminals to monoclonal antibodies. Biochim. Biophys. Acta 1234:74-80.
63. Nezlin, R.C. 1977. Structure and biosynthesis of antibodies. Consultants Bureau, New York, NY, p. 174.
64. Kenworthy, A.K., Simon, S.A. and Mclntosh, T.J. 1995. Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol). Biophys. J. 68:1903-1920.
65. Lee, K.-D., Nir, S. and Papahadjopoulos, D. 1993. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 32: 889-899.
66. Goren, D., Horowitz, A.T., Zalipsky, S., Woodle, M.C., Yarden, Y. and Gabizon, A. 1996. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer 74:1749-1756.
67. Suzuki, S., Uno, S., Fukuda, Y., Aoki, Y., Masuko, T. and Hashimoto, Y. 1995. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br. J. Cancer 72:663-668.
68. Gabizon, A., Huberty, J., Straubinger, R., Price, D.C. and Papahadjopoulos, D. 1988. An improved method for in vivo tracing and imaging of liposomes using Gallium-67- deferoxamine complex. J. Liposome Res. 1:123-135.
69. Heitjan, D.F. 1991. Generalized Norton-Simon models of tumour growth. Statistics in Medicine 10:1075-1088.
70. Matzku, S., Krempel, H., Weckenmann, H.-P., Schirrmacher, V., Sinn, H. and Stricker, H. 1990. Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver métastases. Cancer Immunol. Immunother. 31:285-291.
71. Hong, K., Friend, D.S., Glabe G.G. and Papahadjopoulos, D. 1983. Liposomes containing colloidal gold are a useful probe of liposome-cell interactions. Biochim. Biophys. Acta 732:320-323.
72. Huang, S.K., Lee, K.-D., Hong, K., Friend, D.S. and Papahadjopoulos, D. 1992. Microscopic localization of sterically stabilized liposomes in coloncarcinoma bearing mice. Cancer Res. 52:5135-5143.
73. Madden, T.D., Harrigan, P.R., Tai, L.C., Bally, M.B., Mayer, L.D., Redelmeier, T.E., Loughrey, H.C., Tilcock, C.P., Reinish, L.W. and Cullis, P.R. 1990. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem. Phys. Lipids 53:37-46.
74. Janknegt, R. 1996. Liposomal formulations of cytotoxic drugs. Supportive Care Cancer, 4:298-304.